دورية أكاديمية
أعرض في EDS

Fracture risk remains reduced one year after discontinuation of risedronate.

التفاصيل البيبلوغرافية
العنوان: Fracture risk remains reduced one year after discontinuation of risedronate.
المؤلفون: Watts NB; University of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA. nelson.watts@uc.edu, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A
المصدر: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2008 Mar; Vol. 19 (3), pp. 365-72. Date of Electronic Publication: 2007 Oct 16.
نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: England NLM ID: 9100105 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0937-941X (Print) Linking ISSN: 0937941X NLM ISO Abbreviation: Osteoporos Int Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London, UK : Springer International, c1990-
مواضيع طبية MeSH: Bone Density Conservation Agents/*administration & dosage , Etidronic Acid/*analogs & derivatives , Osteoporosis, Postmenopausal/*drug therapy , Spinal Fractures/*prevention & control, Aged ; Aged, 80 and over ; Biomarkers/urine ; Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Calcium/therapeutic use ; Collagen Type I/urine ; Double-Blind Method ; Drug Administration Schedule ; Etidronic Acid/administration & dosage ; Etidronic Acid/therapeutic use ; Female ; Femur Neck/physiopathology ; Follow-Up Studies ; Humans ; Lumbar Vertebrae/physiopathology ; Middle Aged ; Osteoporosis, Postmenopausal/complications ; Osteoporosis, Postmenopausal/physiopathology ; Peptides/urine ; Risedronic Acid ; Spinal Fractures/etiology ; Spinal Fractures/physiopathology
مستخلص: Unlabelled: One year after discontinuation of three year's treatment with risedronate, BMD decreased at the lumbar spine and femoral neck and bone turnover markers returned to control group levels. Despite these changes, the risk of new morphometric vertebral fractures remained lower in previous risedronate patients compared with previous control patients.
Introduction: Differences in bisphosphonate pharmacology and pharmacokinetics could influence persistence or resolution of the effects once treatment is stopped. We investigated changes in intermediate markers--bone mineral density (BMD) and bone turnover markers (BTM)--and fracture risk after discontinuation of treatment with risedronate.
Methods: Patients who received risedronate 5 mg daily (N = 398) or placebo (N = 361) during the VERT-NA study stopped therapy per protocol after 3 years but continued taking vitamin D (if levels at study entry were low) and calcium and were reassessed one year later.
Results: In the year off treatment, spine BMD decreased significantly, but remained higher than baseline (p < or = 0.001) and placebo (p < 0.001), with similar findings at the femoral neck and trochanter. Urinary NTX and bone-specific alkaline phosphatase, which decreased significantly with treatment, were not significantly different from placebo after 1 year off treatment. Despite the changes in intermediate markers, the incidence of new morphometric vertebral fractures was 46% lower in the former risedronate group compared with the former placebo group (RR 0.54 [95% CI, 0.34, 0.86, p = 0.009]).
Conclusions: Despite the apparent resolution of effect on BMD and BTM, the risk reduction of new vertebral fractures remained in the year after treatment with risedronate was stopped.
References: Bone. 2003 Feb;32(2):120-6. (PMID: 12633783)
J Oral Maxillofac Surg. 2004 May;62(5):527-34. (PMID: 15122554)
J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301. (PMID: 15598694)
N Engl J Med. 2002 Feb 28;346(9):653-61. (PMID: 11870242)
Clin Ther. 2005 Jan;27(1):1-11. (PMID: 15763602)
JAMA. 2006 Dec 27;296(24):2927-38. (PMID: 17190893)
JAMA. 1999 Oct 13;282(14):1344-52. (PMID: 10527181)
Curr Med Res Opin. 2004 Apr;20(4):433-9. (PMID: 15119979)
JAMA. 2006 Dec 27;296(24):2968-9. (PMID: 17190899)
Calcif Tissue Int. 2004 Feb;74(2):129-35. (PMID: 14648009)
Ann Intern Med. 2002 Dec 3;137(11):875-83. (PMID: 12458987)
Ann Intern Med. 2006 May 16;144(10):753-61. (PMID: 16702591)
Bone. 2005 Jul;37(1):1-9. (PMID: 15894527)
Calcif Tissue Int. 2004 Dec;75(6):462-8. (PMID: 15455188)
J Bone Miner Res. 2003 Jun;18(6):1051-6. (PMID: 12817758)
J Bone Miner Res. 2004 Mar;19(3):394-401. (PMID: 15040827)
N Engl J Med. 2004 Mar 18;350(12):1189-99. (PMID: 15028823)
Bone. 2004 Apr;34(4):736-46. (PMID: 15050906)
J Clin Densitom. 2004 Fall;7(3):255-61. (PMID: 15319494)
Calcif Tissue Int. 2003 Nov;73(5):423-32. (PMID: 12964065)
J Bone Miner Res. 2005 Dec;20(12):2097-104. (PMID: 16294263)
J Bone Miner Res. 2004 Aug;19(8):1250-8. (PMID: 15231011)
JAMA. 2001 Feb 14;285(6):785-95. (PMID: 11176917)
Am J Med. 1997 Oct;103(4):291-7. (PMID: 9382121)
J Bone Miner Res. 2004 Aug;19(8):1259-69. (PMID: 15231012)
Am J Med. 2002 Mar;112(4):281-9. (PMID: 11893367)
Osteoporos Int. 2005 Jul;16(7):842-8. (PMID: 15580479)
المشرفين على المادة: 0 (Biomarkers)
0 (Bone Density Conservation Agents)
0 (Collagen Type I)
0 (Peptides)
0 (collagen type I trimeric cross-linked peptide)
KM2Z91756Z (Risedronic Acid)
M2F465ROXU (Etidronic Acid)
SY7Q814VUP (Calcium)
تواريخ الأحداث: Date Created: 20071017 Date Completed: 20080718 Latest Revision: 20220331
رمز التحديث: 20231215
DOI: 10.1007/s00198-007-0460-7
PMID: 17938986
قاعدة البيانات: MEDLINE
الوصف
تدمد:0937-941X
DOI:10.1007/s00198-007-0460-7